Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Marvel Biosciences receives Japanese patent for MB-204

By The Northwire Desk — AI Analysis Feb 04, 2026 · 02:09 MRVL · 0.135 Marvel Biosciences Corp
MRVL · Price

Executive Summary

  • Marvel Biosciences received a Japanese patent (No. 2022-554855) for its lead therapeutic candidate, MB-204, covering composition of matter and methods of use.
  • This marks the second major jurisdiction to grant a composition-of-matter patent for MB-204, strengthening the company's global intellectual property portfolio.
  • MB-204 is a novel fluorinated analogue of istradefylline, currently showing robust preclinical efficacy in models of depression, autism (including Rett syndrome), and fragile X syndrome.

Key Details

  • Patent Details: Japan Patent Office granted Japanese patent No. 2022-554855, titled "Purine Compounds for Treating Disorders."
  • Scope: The patent covers composition of matter and methods of use claims for MB-204.
  • Strategic Impact: CEO Rod Matheson stated this strengthens the global IP portfolio and enhances long-term value as the company advances toward clinical development.
  • Drug Profile: MB-204 is a novel fluorinated analogue of istradefylline (an approved adenosine A2A receptor antagonist for Parkinson's disease).
  • Preclinical Data:
    • Demonstrated improved pharmacokinetics relative to the parent compound.
    • Completed preclinical toxicology testing.
    • Showed robust preclinical efficacy in models of depression.
    • Showed efficacy in multiple models of autism, including Rett syndrome.
    • Currently being evaluated in fragile X syndrome models.
  • Market Context: Autism spectrum disorder affects approximately one in 36 children by age eight. Marvel believes MB-204's differentiated profile and patent coverage position it for continued development and potential strategic partnerships.

Notable Quotes

  • "This represents the second major jurisdiction to grant a composition-of-matter patent for our lead molecule MB-204. Securing patent protection in Japan significantly strengthens our global intellectual property portfolio and further enhances the long-term value of MB-204 as we advance toward clinical development." — Rod Matheson, Chief Executive Officer
Read the original news release →

More from Marvel Biosciences Corp

Jun 08, 2026 · 07:00

Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204

M&A / Property Apr 23, 2026 · 07:30

Marvel Biosciences Secures Funding and Patent Protection for Phase 1 Neurodevelopmental Candidate MB-204

Other Apr 17, 2026 · 16:30

Marvel Biosciences Closes Financing to Fuel Phase I Transition Amidst Patent Wins

Financings Apr 16, 2026 · 07:00

Marvel Biosciences Advances MB-204 Formulation Ahead of Phase I, But Data Integrity Concerns Linger

Other Apr 13, 2026 · 17:31

Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel's Proposed Convertible Debenture Offering

Financings Apr 08, 2026 · 16:31

Small convertible debenture adds cash but raises dilution risk amid mounting debt

Financings